<DOC>
	<DOCNO>NCT01611467</DOCNO>
	<brief_summary>Part 1 : To characterize biotransformation excretion CC-223 follow single 20-mg oral dose CC-223 capsule contain microtracer [ 14C ] -CC-223 solution healthy male subject ; evaluate tolerability CC-223 single 20-mg oral dose CC-223 capsule contain microtracer [ 14C ] -CC-223 solution healthy male adult subject Part 2 : To evaluate effect high-fat meal pharmacokinetics ( PK ) CC-223 follow single 20-mg oral dose CC-223 tablet ; To evaluate effect high-fat meal PK M1 , principal pharmacologically-active metabolite , follow single 20-mg oral dose CC-223 tablet ; evaluate tolerability CC-223 single 20-mg oral dose CC-223 tablet healthy male adult subject .</brief_summary>
	<brief_title>A Phase 1 Open-Label Study Evaluate Metabolism Excretion CC-223 Effect Food Pharmacokinetics CC-223 Healthy Male Adult Subjects</brief_title>
	<detailed_description>This single-center , 2-part , open-label , randomize ( Part 1 ) , 2-treatment study healthy adult male ( n = 18 ) . Within 28 day ( Day -28 ) prior start Part 1 Part 2 , subject undergo routine screening procedure include physical examination , 12-lead electrocardiogram ( ECGs ) , vital sign , clinical laboratory safety test ( serum chemistry , hematology , urinalysis ) , serology screen , fast glucose level ( include HbA1C ) drug alcohol screen . In Part 1 , subject ( n = 6 ) receive Treatment A ( Cohort 1 ) fast condition . Treatment A : A single 20-mg oral dose CC-223 capsule contain microtracer [ 14C ] - CC-223 solution . For Part 1 , subject domicile study center Day -1 morning Day 8 . Upon satisfactory safety review completion study-related procedure , subject discharge study center morning Day 8 . Part 2 2-period crossover study ; Period 1 , subject ( n = 12 ) randomize receive oral 20 mg dose CC-223 ( Treatment B ) fed ( n = 6 ) fast ( n = 6 ) condition . In Period 2 , subject receive Treatment B converse condition base treatment assignment Period 1 ( Cohort 2 3 ) . Fed subject serve standard high fat meal ( breakfast ) , equivalent , must consume within 30 minute serve . Dosing must occur 30 minute ( ±5 minute ) serve subject breakfast . All subject remain fasted 4 hour post dose . Subjects domicile study center Day -1 morning Day 5 period . Subjects discharge study center morning Day 5 upon satisfactory safety review completion study-related procedure . Periods 1 2 separate washout period least 7 day ( 10 day ) prior dose next dose . In certain instance , long washout may acceptable previously agree principal investigator ( PI ) Celgene . All subject return clinic within 7 10 day day discharge Part 1 Period 2 Part 2 follow-up safety assessment .</detailed_description>
	<criteria>1 . Must understand voluntarily sign write informed consent document ( ICD ) prior studyrelated procedure perform able adhere restriction examination schedule . 2 . Must able communicate investigator clinical staff understand comply requirement study . 3 . Must male 18 55 year age ( inclusive ) time sign ICD , body mass index ( BMI ) ( weight [ kg ] / ( height [ m2 ] ) 18 33 kg/m2 ( inclusive ) weight 60 100 kg ( 132 220 lb ; inclusive ) 4 . Must healthy ( Screening Day 1 ) determine investigator basis medical history , physical examination , clinical laboratory safety test result , vital sign , 12 lead electrocardiogram ( ECGs ) . Vital sign ( systolic diastolic blood pressure , pulse rate , oral body temperature ) assess supine position subject rest least 5 minute . Subject must afebrile ( febrile define ≥ 38.5ºC 101.3 Fahrenheit ) Systolic blood pressure range 90 140 mmHg , diastolic blood pressure range 60 90 mmHg , pulse rate range 45 100 bpm Screening fast plasma glucose value within normal limit institution HbA1C &lt; 6 % 5 . Subjects ( without vasectomy ) must agree use barrier contraception ( ie , latex condom nonlatex condom make natural [ animal ] membrane [ eg. , polyurethane ] ) one method ( eg. , spermicide ) engage sexual activity woman childbearing potential study conduct , 90 day last dose study medication . 6 . Must agree refrain donate blood plasma ( study ) participate study least 28 day last dose study drug . 1 . Recent history ( ie , within 3 year ) clinically significant neurological , gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , endocrine , hematological , dermatological , psychological , major disorder . 2 . Any condition , include presence laboratory abnormality , place subject unacceptable risk participate study , confound ability interpret data study . 3 . Use prescribed systemic topical medication within 30 day first dose . 4 . Use nonprescribed systemic topical medication ( include herbal medicine ) within 7 day first dose administration ( exception vitamin/mineral supplement ) . 5 . Subject use metabolic enzyme inhibitor inducer ( ie , CYP3A inducers inhibitor St. John 's Wort ) within 30 day first dose administration . 6 . Presence surgical medical condition possibly affect drug absorption , distribution , metabolism , excretion , plan elective medical procedure conduct trial . 7 . Exposure investigational drug ( new chemical entity ) within 90 day prior first dose administration . 8 . Donation blood plasma within 60 day prior first dose administration . 9 . History multiple ( ie , 2 ) drug allergy . 10 . Any clinical significant allergic disease ( exclude nonactive hay fever ) , exclude nonactive seasonal allergy childhood asthma clear least 3 year 11 . History drug abuse within 2 year prior first dose , positive urine drug screen test due illicit drug . 12 . History alcohol abuse within 2 year prior dose , positive alcohol screen . 13 . Smokes 10 cigarette , consumes equivalent tobacco , per day . 14 . Known , test positive , active chronic hepatitis B hepatitis C , human immunodeficiency virus ( HIV ) antibodies 15 . Received vaccination ( exclude seasonal flu vaccination ) within 90 day study drug administration . 16 . For Part 1 Only : Prior exposure radioactive investigational drug within 6 month prior check , prior exposure workrelated , diagnostic therapeutic radiation within 12 month prior check .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>CC-223</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>AME ( Absorption , Metabolism , Excretion )</keyword>
	<keyword>FE ( Food Effect )</keyword>
</DOC>